Boehringer Ingelheim continues providing non assert declarations to manufacture HIV/AIDS medicines

Boehringer Ingelheim continues to be willing to provide WHO qualified generic pharmaceutical companies non assert declarations to manufacturer and export products containing the HIV/AIDS medication nevirapine to Rwanda and other defined developing countries.

Canada has taken a leadership role through the Canadian Access to Medicines Regime (CAMR) to provide a framework to allow important patented HIV/AIDS medications to reach the developing world.

Boehringer Ingelheim has repeatedly stated that patents must not prevent HIV patients from having access to life-saving anti-HIV drugs in resource limited settings. In order to accelerate access to anti-retroviral medicines, the company initiated non-assert declarations in May 2007 (one of these declarations was previously granted to Apotex for the purpose of the initial Rwandan shipment of the combination product).

The non-assert declaration means that the company will not enforce its patent rights against the agreement partner. The company has further waived the provision of a nominal royalty fee under the access policy so the partnering companies can supply the nevirapine containing drugs without any payments to Boehringer Ingelheim. Generic manufacturers whose nevirapine product and production site have been pre-qualified by WHO are enabled to supply in total 78 countries which are either Least Developed Countries (LDC) according to the UNDP classification, or low income countries according to the World Bank classification and all other countries in Africa.

By providing only WHO pre-qualified generic producers with the non-assert declaration the quality of nevirapine is guaranteed. This is crucial in countries with weak or non-existent Drug Regulatory Authorities and is in line with our Corporate Responsibility.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus